Therapy with [188Re]Re(HEDP) has demonstrated an improvement in overall survival and progression-free survival in patients with bone metastases and even a reduction in prostate-specific antigen (PSA) levels in metastatic castration-resistant prostate cancer patients. The gene discussed is KLK3; the disease is prostate carcinoma.